Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Full approval could encourage more people to get vaccinated and raises the prospect of off-label use.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Three decades ago, HIV advocates helped lay the groundwork for the response to COVID-19.
Alzheimer’s advocates laud the approval of Aduhelm, but experts raise questions about its effectiveness and cost.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
The Johnson & Johnson vaccine, which is easier to store and deliver, will help speed up the coronavirus vaccine rollout.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Moderna’s coronavirus vaccine is 94% effective in preventing symptomatic COVID-19—and it may also reduce asymptomatic infection.
The test is authorized for individuals two years of age or older, including those not showing symptoms.
Pfizer/BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.